The relation between the results of the HPV-Oncotect®, the cytological alterations, the risk factors and the viral genotype determined by PCR in peri and post menopausic patients;Relación entre el resultado del HPV-Oncotect®, las alteraciones citológicas, los factores de riesgo y el genotipo viral determinado por PCR en pacientes peri y postmenopáusicas

Ginecologia y Obstetricia Clinica

Volumn 9, Issue 3, 2008, Pages 181-186

  González, Silvia P ^a,c   Henríquez, Alexandra ^b   De La Cuesta, Ricardo Sainz ^b  

^a Unidad de Menopausia Y Osteoporosis   (Spain)

^b HOSPITAL QUIRÓN   (Spain)

^c Gabinete Médico Velázquez ^*  (Spain)

Author keywords

HPV PCR; Human Papiloma virus; Oncogenic risk; Oncotect

Indexed keywords

PROTEIN E6; PROTEIN E7;

ADULT; ARTICLE; BIOCHEMICAL EQUIPMENT; CANCER RISK; CARCINOGENESIS; CLIMACTERIUM; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPATHOLOGY; FEMALE; GENOMICS; GENOTYPE; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PATIENT SELECTION; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PROTEIN EXPRESSION; UTERINE CERVIX CANCER; WART VIRUS;

EID: 55249118659     PISSN: 16953827     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer 1999;80:827-41.
2. Walboomers JMM, Jacobs MV, Manos MM, Bosch XF, Kupek E, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
4. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27.
5. Bosch, et al. Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol Biomarkers Prev 1995;4(5):459-67.
6. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50. Review
7. de Boer, et al. High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients. Clin. Cancer Research 2007;13(1).
8. Lie AK, et al. DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecologic Oncology 2005;97:908-15.
9. Molden, et al. Comparison of Human Papillomavirus Messenger RNA and DNA Detection: A Cross-sectional Study of 4,136 Women >30 Years of Age with a 2-Year Follow-up of High-Grade Squamous Intraepithelial Lesion. Cancer Epidemiology Biomarkers & Prevention 2005;14:367-72.
10. Molden, et al. Predicting CIN2+ when detecting HPV mRNA and DNA by Pre-Tect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL pap smear. International Journal of Cancer 2005;114(6):973-6.
11. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br J Cancer 2004;90:1407-13.
12. Narimatsu R, Patterson BK. High-Throughput Cervical Cancer Screening Using Intracellular HPV E6 and E7 mRNA Quantification by Flow Citometry. Stanford, CA: Medical School 2005.
13. Massad LS, Collins YC, Meyer PM. Biopsy correlates of abnormal cervical cytology classified using the Bethesda system. Gynecol Oncol 2001;82(3):516-22.
14. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 1987;6:139-44.
15. Snijders, et al. HPV-mediated cervical carcinogenesis: concepts and clinical implications. J Pathol 2006;208:152-64.
16. Puig-Tintoré LM. Prevención del cancer de cuello uterino ante la vacunación trente al virus del papiloma humane Progr. Obstet. Ginecol 2006;49(Supl 2):5-62.
17. a Monografía de la Sociedad Española de Epidemiología, EMISA, SEE 2006. Capítulo 8, p. 141-7.
18. Sellors JW, Karwalajtys TL, Kaczorowski JA, Mahony JB, Lytwyn A, Chong S, Sparrow J, Lorincz A. Survey of HPV in Older Ontario Women (SHOOW) Group. Prevalence of infection with carcinogenic human papillomavirus among older women. CMAJ 2002;167(8):871-3.
19. zur Hausen, H. Intracellular surveillance of persisting viral infections. Human genital cancer results from deficient cellular control of papillomavirus gene expression. Lancet U 1986;489-91.
20. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactrvation. Pharmacol Ther 1998;78:129-39.
21. Munger, et al. The cytokines tumor necrosis factor-alpha (TNF-alpha) and TNF-related apoptosis-inducing ligand differentially modulate proliferation and apoptotic pathways in human keratinocytes expressing the human papillomavirus-16 E7 oncoprotein. J Biol Chem 2001;276(25):22522-8.
22. Reinstein E, Scheffner M, Oren M, Ciechanover A, Schwartz A. Degradation of the E7 human papillomavirus oncoprotein by the ubiquitin-proteasome system: targeting via ubiquitination of the N-terminal residue. Oncogene 2000;19:5944-50.
23. Fiedler, et al. High level HPV-16 E7 oncoprotein expression correlates with reduced pRb-levels in cervical biopsies. The FASEB Journal 2004;18(7).
24. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990;63(6):1129-36.
25. Dyson N, Howley PM, Münger K, Harlow E. The human papillomavirus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243:934-7.
26. Romanczuk H, Villa L, Schlegel R, Howley PM. The viral transcriptional regulatory region of the E6 and E7 genes is a major determinant of the differential immortalization activities of human papilomavirus 16 and 18. J. Virol 1991;65:2739-44.
27. Munger K, Yee CL, Phelps C, et al. Biochemical and biological differences between E7 oncoproteins of the high and low-risk human papillomavirus types are determined by amino-terminal sequences. J. Virol. 1991;65:3943-8.
28. Herrington CS. Do HPV-negative cervical carcinomas exist? J Pathol. 1999;189(1):1-3.
29. Schiffman M, Wheeler C, Dasgupta A, Solomon D, Catle PE, for the ALTS group. A comparison of a prototype PCR assay and hybrid capture 2 for detection of carcinogenic human papilomavirus DNA in women with equivocal or midly abnormal Papanicolau smears. Am J Clin Pathol 2005;124:1-11.
30. González Rodríguez SP, Hernández Aguado JJ, Ojeda Jabardo MD. Relación entre el resultado del HPV-ONCOTECT y el genotipo viral determinado por PCR. En: Cd-rom de ponencias del XXIX Congreso de la Sociedad Española de Ginecología y Obstetricia, Granada 2007.
31. González Rodríguez SP, Hernández Aguado JJ, Ojeda Jabardo MD. Relación entre el resuttado del HPV-ONCOTECT y los hallazgos citológicos en pacientes asintomáticas. PCR. En: Cd-rom de ponencias del XXIX Congreso de la Sociedad Española de Ginecología y Obstetricia, Granada 2007.
32. Kyo S, Klumpp J, Inoue M, Kanaya T, Laimins. Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified. J Gen Virol 1997;78:401-11.
33. Meijer CJLM, Walboomers JMM. Cervical cytology alter 2000: where to go? J Clin Pathol 2000;53:43.
34. Davey DD. Cervical Cancer Screening: Will Human Papillomavirus Testing Replace Citology? Journal of Lower Genital Tract Disease, 2004;8(1):6-9.
35. Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, Matcher DB. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132(10):810-9.